facebook twitter linkedin
rd offer

This material was prepared by a third party towards Selvita S.A. with its registered office in Kraków (hereunder: “Selvita”). Within the scope which was not authorized by Selvita’s management board, the description of factual circumstances regarding the activities of Selvita, embodied in this material presents merely opinion of the third party, in particular with respect to presented opinions, predictions, appraisals and forecasts of the financial data and future activity of Selvita and its results.

Therefore, Selvita does not warrant consistency of this material with the actual and legal situation. Neither Selvita, members of its corporate bodies, employees nor its consultants shall bear any liability for validity of opinions, predictions, appraisals, forecasts and any other date embodied in this material as well as for consequences of actions of any reader made on a basis of this material, in particular for the investment decisions or any losses resulting from use of this material.

Readers of this material shall make its own assessment, whether opinions or forecasts embodied therein are credible and adequate, in particular taking into account their investment strategy and actual and legal situation. In particular they should consult it with their independent financial and investment advisors. None of the information presented in this material shall constitute investment, legal, accounting or tax advice or a statement that any investment strategy is accurate or adequate, considering the circumstances of the reader.

Furthermore date presented in this material shall not constitute an offer to sell or purchase any financial instruments nor an invite the make such offer. It shall not be also not deemed as a recommendation for investment in any financial instrument nor an advertisement of such instruments.



DISAGREE AGREE

Kinase discovery platform

There are more than 500 distinct protein kinases in the cell that form a complex interaction network and by reversible protein phosphorylation regulate intracellular signal transduction. Dysfunction of kinase activity can cause many human diseases and since protein kinases are critical initiators, mediators and amplifiers of multiple signaling pathways associated with malignant transformation and aggressiveness of the disease, they remain a major focus of research initiatives identifying novel targeted therapies. Selvita started its first kinase discovery programs in 2008. Set of research tools developed within the platform enables fast target validation and the rapid and effective development of kinase inhibitors.

In September 2013 Selvita entered into strategic partnership with the US based biotech company - H3 Biomedicine. The aim of the joint project is development of innovative anticancer therapies with the use of small molecule inhibitors acting on two novel kinase targets associated with oncogenic signaling pathways in cancer.